BioPharma Resources

Drug Trial Radar · NCT05397496

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

A Phase I, Open-label, Multi-center Study of PIT565 in Patients With Relapsed and/or Refractory B-cell Malignancies

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

61

Actual

Start

Oct 3, 2022

Primary completion

May 31, 2027

Study completion May 31, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

Conditions

  • B-cell Non-Hodgkin Lymphoma (B-NHL)
  • B-cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions

  • PIT565Biological

    Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of Dose Limiting Toxicities (DLTs)Time frame: 28 days or 35 days, depending on the dosing schedule
  2. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 21 months
  3. Frequency of dose interruptionsTime frame: 21 months
  4. Frequency of dose reductionsTime frame: 21 months
  5. Dose intensitiesTime frame: 21 months

Locations

18 sites in 9 countries. Site status is shown where the registry gives one.

  • University Of Miami

    Miami, Florida

  • University of Chicago Medical Center

    Chicago, Illinois

  • The University of Kansas Clinical Research Ctr

    Fairway, Kansas

  • Memorial Sloan Kettering Cancer Ctr

    New York, New York

  • Oregon Health Sciences University

    Portland, Oregon

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Tianjin, China

  • Novartis Investigative Site

    Créteil, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Tel Aviv, Israel

  • Novartis Investigative Site

    Reggio Emilia, RE, Italy

  • Novartis Investigative Site

    Kashiwa, Chiba, Japan

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.